FINANCIAL STATEMENTS Notes to the Consolidated Financial Statements Continued 16.
Investments in associates and joint ventures 17.
Deferred tax continued Certain deferred tax assets and liabilities have been appropriately offset.
The following is the analysis of the deferred tax balances after A loss of $2 million representing the Group share of the results of Unimark Remedies Limited and Hubei Haosun Pharmaceutical Co. Ltd offset for financial reporting purposes: 2014: share of loss $6 million.
During 2015, the Group has impaired the remaining investment balance related to Unimark Remedies As at 31 December Limited of $7 million which is due to the continuous financial difficulties.
Hikmas share in Unimark Remedies Limited is being divested during 2015 2014 2016 for minimal value.
$m $m The below represents the Groups share of the result and the impairment of Unimark Remedies Limited and Hubei Haosun Pharmaceutical Deferred tax liabilities 21 25 Co. Ltd.
Both are included in the consolidated income statement.
Deferred tax assets 70 67 49 42 For the year ended For the year ended 31 December 2015 31 December 2014 No deferred tax asset has been recognised on temporary differences totalling $164 million 2014: $86 million due to the unpredictability of Joint Joint the related future profit streams.
Of these temporary differences, $40 million relates to unrecognised deferred tax on UK share-based Associates Total ventures Associates Total ventures payments.
The remaining temporary difference of $ 124 million relates to losses on which no deferred tax is recognised.
None of these losses $m $m $m $m $m $m are expected to expire.
Balance at 1 January 3 13 16 3 19 22 Share of loss 2 2 6 6 No deferred tax liability is recognised on temporary differences of $122 million 2014: $96 million relating to the unremitted earnings of Impairment of investment note 5 7 7 overseas subsidiaries, as the Group is able to control the timing of the reversal of these temporary differences and it is probable that they will Balance at 31 December 3 4 7 3 13 16 not reverse in the foreseeable future.
Summarised financial information in respect of the Groups interests in associated companies is set out below: 18.
Financial and other non-current assets For the year For the year As at 31 December ended ended 2015 2014 31 December 31 December $m $m 2015 2014 $m $m Other financial assets 1 Total assets 214 220 Available-for-sale investments 2 1 Total liabilities 160 148 Other non-current asset 44 37 Net assets 54 72 46 39 Group's share of net assets of associates 13 17 Other non-current assets mainly represent advance payments made to acquire products and product related technologies from third parties.
Total revenue 49 50 These payments will be reclassified to intangible assets and inventory from the point where the products are available for use.
Net loss 23 27 Group's share of loss of associates 2 6 19.
Deferred tax 2015 2014 $m $m The following are the major deferred tax liabilities and assets recognised by the Group and movements thereon during the current and prior Finished goods 55 60 reporting years.
Work-in-progress 33 33 Raw and packing materials 152 159 Other short-term Goods in transit 11 21 Deferred R&D temporary Amortisable Share-based 251 273 Tax losses costs differences assets Fixed assets payments Total $m $m $m $m $m $m $m Goods in transit includes inventory held at third parties whilst in transit between Group companies.
At 1 January 2014 1 89 22 9 1 60 As at As at Charge Credit to income 4 12 1 7 31 December Translation 31 December Acquisition of business 13 13 ` 2014 Additions Utilisation adjustments 2015 Exchange differences 2 2 $m $m $m $m $m At 1 January 2015 4 1 77 20 22 2 42 Provisions against inventory 50 29 31 1 47 Credit Charge to income 1 3 1 6 5 The total expense in the consolidated income statement for the write-off of inventory, including provisions for such write-offs, was $29 Charge to equity 1 1 million 2014: $32 million.
